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Background and Objectives: Krill oil (KO) and fish oil (FO) are good sources of health-benefiting long chain n-
3 polyunsaturated fatty acids (LC n-3 PUFA), EPA and DHA. There are conflicting outcomes on the bioavailabil-
ity of LC n-3 PUFA from KO compared with FO. This study investigated the postprandial incorporation of LC n-
3 PUFA into plasma lipids following consumption of 5 capsules of KO or FO in comparison with olive oil (OO) 
control in healthy women. Methods and Study Design: 10 women (aged 18-45 years) consumed a high-fat (15 g) 
breakfast, supplemented with 5 g of KO, FO, or OO in a random order with a minimum seven-day washout peri-
od between the supplementations. The LC n-3 PUFA content in KO was 907 mg compared with 1441 mg in FO. 
Blood samples were collected in the fasting state and for the next 5 hours after test meal consumption on an 
hourly basis. Results: Significant increases in plasma EPA concentrations were observed starting at 2 h after KO 
and FO consumption (p<0.05). There were no significant changes in either DHA or DPA between the three 
groups. The increases in plasma EPA concentrations were similar between the KO and FO groups (p>0.05). Con-
clusions: The lower dose (31%) of EPA from KO led to a similar plasma EPA concentration as in the FO group, 
suggesting that EPA from KO may be more efficiently incorporated into plasma. This may be related to the high 
content of phospholipids and free fatty acids in KO. 
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INTRODUCTION 
The long-chain omega-3 polyunsaturated fatty acids (LC 
n-3 PUFA) eicosapentaenoic acid (EPA, C20:5n-3) and 
docosahexaenoic acid (DHA, C22:6n-3) have been rec-
ommended for cardiovascular disease prevention.1,2 LC n-
3 PUFA reduce plasma triglycerides,3 inflammatory 
cytokines and C-reactive protein levels.4,5 EPA and DHA 
have different biological functions.6,7 EPA directly com-
petes with arachidonic acid (AA, 20:4n-6) in relation to 
the production of anti- and pro-inflammatory lipid media-
tors including eicosanoids, resolvins, and maresins.8 
Moreover, EPA-derived eicosanoids are associated with 
anti-platelet aggregation and vasodilation.9 DHA plays an 
essential role in the development of the central nervous 
system and visual function.10 Another LC n-3 PUFA is 
DPA, although to date there are limited health benefits, it 
has shown positive effects on platelet function in vivo.11 
Although these LC fatty acids can be synthesised via en-
zymatic desaturation and elongation from alpha-linolenic 
acid, (ALA, 18:3n-3), the conversion rate from ALA in 
humans is very low (approx. 5% for EPA and <0.5% for 
DHA).12-14 Therefore, humans largely rely on dietary 
sources, especially seafood such as oily fish (mackerel,  
 
 
tuna, salmon, herring) and shellfish for these important 
fatty acids.15,16 It has been well reported that the level of 
EPA and/or DHA in the plasma and erythrocytes can be 
increased following the consumption of seafood or sup-
plementation with marine oils.17-20 
Human consumption of fish-derived food products has 
increased steadily, and the global capture of fish will be-
come unsustainable in the future. Krill, a shrimp-like ma-
rine zooplankton, has been identified as an alternative 
source due to its wide and abundant distribution.15 The 
main commercially available krill oil is extracted from 
Antarctic krill (Euphausia superba), living in the South-
ern Ocean, and it has become an important source of LC 
n-3 PUFA in the last decade.15 In krill oil, EPA and DHA  
 
Corresponding Author: Assoc/Prof Xiao Q Su, Centre for 
Chronic Disease, College of Health and Biomedicine, Victoria 
University, P.O. Box 14428, Melbourne, VIC 8001, Australia. 
Tel: +61-3-99192318; Fax: +61-3-99192645 
Email: xiao.su@vu.edu.au 
Manuscript received 05 July 2017. Initial review completed 16 
July 2017. Revision accepted 26 July 2017. 
doi: 10.6133/apjcn.092017.03 
                                                              Postprandial n-3 PUFA response to krill oil                                                        149                                
are found in the phospholipid fraction (predominantly 
phosphatidylcholine), free fatty acids, and in the triglycer-
ides (TAG) whereas in fish oil they are mainly in 
TAG.15,21,22 Previous studies have suggested that LC n-3 
PUFA from phospholipids (PL) may lead to a more effi-
cient incorporation of these fatty acids into plasma and 
erythrocytes compared with those esterified to TAG.17,23 
There are three postprandial studies, which have inves-
tigated the short-term incorporation of LC n-3 PUFA into 
the plasma from krill oil compared with fish oil.17,24,25 
Schuchardt et al17 and Yurko-Mauro et al24 compared krill 
oil with re-esterified fish oil TAG or ethyl-esters fish oil 
while Kohler et al25 compared krill oil with krill meal and 
fish oil over 72 hours. The results from these studies are 
not consistent. Kohler et al25 found a significantly higher 
incorporation of EPA and DHA into the plasma phospho-
lipids from krill oil compared with fish oil. In contrast, 
neither Schuchardt et al17 nor Yurko-Mauro et al24 ob-
served a significantly higher incorporation of EPA and 
DHA into plasma phospholipids from krill oil. These lat-
ter two studies reported substantial variability between 
participants, which limited their capacity to detect signifi-
cant differences between the study oils. There are also 
three longer-term studies, which have compared the bioa-
vailability of LC n-3 PUFA from krill oil with fish 
oil.18,24,26 The only study which reported a significantly 
higher incorporation of EPA from krill oil versus fish oil 
was that of Ramprasath et al.26 Therefore, the information 
available from the literature is not consistent with regards 
to the bioavailability of EPA (and DHA) from krill oil in 
comparison with fish oil. The term “bioavailability” is 
often used in these studies, however true bioavailability 
measures the rate and extent to which a drug/compound 
reaches the systemic circulation.27 In a nutrition context, 
the term bioavailability is similar to digestibility which 
refers to how much of a given nutrient is retained in the 
body; this implies that faecal losses have been estimated 
which is rarely or never the case in n-3 PUFA studies.28 
It has also been reported that there are gender-specific 
differences in the contribution of LC n-3 PUFA in differ-
ent tissues. Compared with men, women tend to have a 
higher omega-3 index,29 and also a significantly higher 
level of both AA and DHA in the total plasma and plasma 
phospholipids.30 Women have also been found to respond 
to n-3 supplementation differently to men.31 Furthermore, 
the influence of age on the gender differences in the fatty 
acid composition has been observed.30  Available studies, 
which have compared the efficacy of krill oil and fish oil, 
have either focused only on male participants or mixed 
gender cohorts, and typically with a wide age range. The 
data from those studies have been conflicting with large 
inter-participant variabilities.17,24,25 The aim of this study 
was to compare the postprandial bioavailability (incorpo-
ration) of equal amounts of krill oil with fish oil in 
healthy young women. This is the first postprandial study 
to compare krill oil with fish oil supplementation in 
young women, which also included a control (olive oil) 
treatment. All participants were recruited from a narrow 
age group (18-45 years) to minimise variations between 
participants. We investigated the effect of a single same 
dose of krill oil in comparison with fish oil on postpran-
dial plasma fatty acid composition, and plasma and chy-
lomicron lipid levels. This study will provide useful in-
formation on how young women respond acutely to krill 
oil supplementation. 
 
METHODS 
Study participants 
Ten healthy women aged between 18–45 years within 
BMI 20–30 (kg/m2), who had not experienced menopause, 
were recruited by emails to all Victoria University staff 
and students, and flyer advertisements via the Victoria 
University Nutritional Therapy Teaching Clinic, the gen-
eral public, community centres, and local medical prac-
tices. Participants were screened for their suitability for 
the postprandial study using a medical questionnaire and 
anthropometric measurements prior to enrolling into the 
study. Participants were excluded if they were cigarette 
smokers; pregnant or lactating; or had heart, liver, kidney 
or inflammatory bowel disease; diabetes; or medications 
interfering with lipid metabolism or lowering blood lipids; 
allergy to fish or seafood; or had consumed oily fish more 
than twice a week or supplements including omega-3 
fatty acids in the past four weeks prior to the study. 
 
Study design 
This study was conducted in accordance with the ethical 
principles outlined in the Declaration of Helsinki and the 
protocol was approved by the Ethics Committee of Victo-
ria University Human Research (HRE 14-040). The writ-
ten informed consent was obtained from all participants 
prior to the study. This trial was registered with the Aus-
tralian and New Zealand Clinical Trial Registry (ACTRN 
12615000620527). The study was a randomised crossover 
design with three test meals supplemented with different 
oils consumed in a randomised order with seven days 
wash-out period between the test meals (Figure 1). Dur-
ing the study period, all participants were instructed to 
maintain their habitual diet and not to consume 
fish/seafood or omega-3 fortified foods more than twice a 
week. 
Prior to the study day, the participants were required to 
consume a low-fat dinner such as pasta, and avoid drink-
ing alcohol and strenuous physical activity, and fast for 
approximately 10 h overnight. On the study day, stand-
ardised procedures were performed where the participants 
arrived at the clinic between 7 a.m. and 9 a.m. and a fast-
ing blood sample (0 h, 10 mL) was collected via intrave-
nous cannulation by a qualified practitioner. The partici-
pants then consumed a single test meal (breakfast), which 
consisted of 150 g of fresh mashed potato mixed with 15 
g of olive oil, together with 5 × 1 g capsules of krill oil or 
5 × 1 g capsules of fish oil with 250 mL of water. Krill oil 
and fish oil are very different in colour, smell, and taste 
so for this trial both oils were provided as capsules rather 
than as oils in order to provide a degree of blinding to the 
trial. For the control treatment, the participants consumed 
5 g of olive oil added into the mashed potato in place of 
the five capsules (1 g each) of the krill oil or fish oil. It 
was recognized that the 5 g of krill oil and fish oil do not 
contain identical amounts of LC n-3 PUFA, but it was 
deemed that was preferable to maintain the test oils as 
blinded a fashion as possible, and minimise the partici-
pants withdrawing from the trial owing to smell and taste 
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considerations. All participants finished the test meal, 
including the capsules, within 15 min and they were only 
allowed to drink water during the intervention period of 5 
h. After the test meal consumption, postprandial blood 
samples (10 mL) were collected at every hour for 5 h, 
thus making a total of six blood samples per participant 
per test meal. 
 
Study oils 
The study oils including krill oil and fish oil capsules 
(both products from Swisse Wellness Pty Ltd., Melbourne, 
VIC, Australia) were purchased from the local pharmacy. 
The fatty acid profile of these oils was analysed using the 
gas chromatography (GC) prior to the commencement of 
intervention. The participants consumed study oils 5 × 1 g 
krill oil capsules or 5 × 1 g fish oil capsules, which equat-
ed to a total EPA, DPA, and DHA intakes of 907 mg for 
the krill oil and 1441 mg for fish oil, as shown in Table 1. 
The equal number of oil capsules was provided with the 
intention of having participants blinded. The single cap-
sule fill weight was 1054 mg for krill oil and 1063 mg for 
fish oil, and these values were used to calculate the EPA, 
DPA, and DHA contents. As expected, the olive oil was 
rich in oleic acid (79%) and devoid of LC n-3 PUFA. The 
krill oil and fish oil were typical of such oils, as reported 
in the literature, and contained 18% and 29% of total LC 
n-3 PUFA, respectively. 
 
Dietary assessment 
Dietary records using a 24 h recall form were analysed to 
identify the LC n-3 PUFA intake using FoodWorks ver-
sion 8 (Xyris software, Brisbane, QLD, Australia) with 
NUTTAB 2010 and AUSNUT 2013 based on Australian 
Food Composition Database. LC n-3 PUFA intake of 
each participant was monitored throughout the study pe-
riod using a 24 h dietary recall each time when the partic-
 
Table 1. LC n-3 PUFA in study oils 
 
 Krill oil  Fish oil 
Per capsule 5 capsules  Per capsule 5 capsules 
LA (18:2n-6), mg 13.3 (0.2)  67   11.9 (0.2)  60  
ALA (18:3n-3), mg 7.2 (0.2)  36   6.6 (0.1)  33  
AA (20:4n-6), mg 6.6 (0.5)  33   14.7 (0.8)  74  
EPA (20:5n-3), mg 108.4 (1.4)  542   157.3 (2.6)  786  
DPA (22:5n-3), mg 13.4 (1.0)  67   36.3 (5.0)  182  
DHA (22:6 n-3), mg 59.5 (0.8)  298   94.6 (2.7)  473  
Total LC n-3 PUFA, mg 181.3  907   288.2  1441  
 
AA: arachidonic acid; ALA: alpha linoleic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; DPA: docosapentaenoic acid; 
LA: linoleic acid. 
Values are expressed as mean (±SE) of five randomly chosen oil capsules mixed together and analysed six times using GC. The total LC 
n-3 PUFA represents the sum of EPA, DHA, and DPA.  
 
 
Figure 1. Flow chart of study design. Each participant, in a random order, received each of the three treatments (olive oil, krill oil, or fish 
oil). There was a seven-day washout between each test meal.  
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ipant visited the clinic. 
 
Identification of lipids in dietary oils 
The lipid classes of test oils were analysed using thin-
layer chromatography (TLC) on silica gel 60 plates 
(Merck, Darmstadt, Germany) together with a standard 
(Nu-Chek Prep Inc., C18-5A) using the solvent mixture 
petroleum ether: diethyl ether: acetic acid (85:15:2, v/v/v). 
The solvent was allowed to equilibrate for at least 20 min 
prior to use. The samples were spotted on silica gel 60 
TLC plates and allowed to develop to within 2 cm of the 
top of TLC plate. The plates were removed and air-dried, 
then sprayed with a solution of dichlorofluorescein in 
methanol (0.05%) and viewed under a UV light.32 The 
only major lipid classes observed in olive oil and fish oil 
were TAG, with a minor band in the sterol region in the 
case of fish oil; in contrast, the krill oil had an obvious 
band in TAG region, a weak band in the free fatty acid 
(FFA) region, and a distinct band at the origin which is 
where phospholipids remain in this solvent system (data 
not shown). 
 
Plasma fatty acid analysis 
Modified transesterification method of Lepage and Roy33 
was used in this study. Briefly, 200 µL blood samples 
were mixed with an internal standard, heneicosanoic acid, 
C21:0 (Nu-Chek Prep, Inc., Elysian, MN, USA) in meth-
anol: toluene (4:1 (v/v)) and then reacted with 200 µL of 
acetyl chloride for 1 h at 100 °C to form fatty acid methyl 
ester (FAME). Then 5 mL of 6% potassium carbonate 
(K2CO3) in distilled water was added and the blend was 
thoroughly vortexed prior to centrifugation at 3000 × g 
for 10 min to separate the layers. The toluene-rich layer 
was removed and evaporated to dryness under nitrogen 
gas, and the FAME was then dissolved in petroleum spirit. 
The resulting FAME was separated by GC (Varian Star 
3400Cx, Agilent Technologies, CA, USA) equipped with 
an SGE BPX 70 capillary column (60 m × 0.25 mm in-
ternal diameter, 0.25 μm film thickness) (SGE Analytical 
Science, Melbourne, Australia), and a flame ionization 
detector (FID). 2 µL of samples were injected in splitting 
mode (1:10) with helium as the carrier gas. The FAME 
was identified by comparison with a standard FAME 
mixture, GLC reference standard 403 (Nu-Chek Prep, 
Inc., Elysian, MN, USA). 
 
Lipid fractions of plasma 
Total lipids were extracted from plasma as described by 
Ghasemifard et al34 and then TAG and phospholipid were 
isolated by thin layer chromatography (TLC). In brief, 
700 µL of plasma was mixed with 3.5 mL of dichloro-
methane: methanol (2:1, v/v) containing 0.01 mg butylat-
ed hydroxytoluene and reference internal lipid standards, 
triheptadecanoin, C17:0 (NuChek Prep, Inc., Elysian, MN, 
USA) and 1, 2-diheptadecan oyl -sn -gl ycer o-3-
phosphocholine, C17:0 (Avanti Polar Lipids, Alabaster, 
AL, USA). Isolated TAG and PL fractions from the TLC 
plates were transmethylated with 5% H2SO4 in methanol 
prior to fatty acid methyl ester (FAME) analysis by GC as 
described above. Due to time constraint, samples from 
four of the 10 participants were randomly chosen for 
analysis of lipid fractions to assess the impact of krill oil, 
fish oil, and olive oil. 
 
Isolation of plasma and chylomicrons 
EDTA blood samples were centrifuged at 3000× g at 4 °C 
for 10 min to obtain plasma. 2.7 mL of the EDTA plasma 
was overlaid with 2.4 mL saline solution (density =1.006 
kg/L) to obtain chylomicron. Fractions were spun using 
ultracentrifugation at 36,000× g at 22 °C for 30 min 
(Sigma 3-30K).35,36 The top layer (approx. 1.5 mL) was 
aspirated to remove the chylomicron fraction. All plasma 
and chylomicron samples were aliquoted into cryotubes 
and kept at −80 °C until further analysis. 
 
Plasma lipid profiles and blood glucose 
The concentration of total cholesterol, TAG, low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL) in 
plasma, and the concentration of total cholesterol and 
TAG in the isolated chylomicron were measured using a 
Thermo Fisher Indiko™ auto-biochemistry analyser by 
enzymatic colorimetric methods using commercially 
available kits (CHOL, Triglycerides, Glucose HK, HDL 
A B) as per the manufacturer’s instructions (Thermo 
Fisher Scientific Inc., Melbourne, VIC, Australia). 
 
Statistical analysis 
The power calculation to determine the minimum number 
of participants to detect a difference in plasma LC n-3 
PUFA, plasma TAG based on a previous postprandial 
study19 was 6, using a two tailed t-test at the 5% signifi-
cance level for a power of 90%. Data were expressed as 
means ± standard error of the mean (SE) except for par-
ticipant characteristics (mean±standard deviation). All 
data were analysed using SPSS version 22 and GraphPad 
Prism version 6.04. Distributions of data were also ana-
lysed for normality prior to data analysis. Postprandial 
plasma fatty acids were analysed to determine the signifi-
cant effects of oil consumption on changes from baseline 
by time, test meal, and interaction between the time and 
test meal using two-way analysis of variance (ANOVA) 
for repeated measures, and post-hoc analysis was under-
taken using the Tukey test. The net incremental area un-
der the curve from baseline (net iAUC) over the post-
prandial period was calculated using the trapezoid rule 
and comparison between the net iAUC of test meals was 
performed using one-way ANOVA for repeated measures 
and the Tukey test for post-hoc comparison. p<0.05 was 
considered significant. 
 
RESULTS 
Participant characteristics and intake of dietary LC n-3 
PUFA at baseline 
The 10 healthy women who completed the crossover 
study with three test meals had a mean age of 28.5±9.3 
years, systolic blood pressure (113±10.9 mmHg) and di-
astolic blood pressure (70.8±9.9 mmHg) with a BMI of 
25.8±3.6 (kg/m2). All participants completed a 24 h die-
tary recall on each study day, which was analysed using 
FoodWorks version 8. The daily intake of LC n-3 PUFA 
from the 24 h recall was 106±91.0 mg. There was no sig-
nificant difference in LC n-3 PUFA intakes from food for 
each participant between the study days. 
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Plasma fatty acid composition 
The participant’s baseline concentrations of EPA, DHA 
or DPA in plasma were not significantly different among 
the three test meals. EPA concentrations significantly 
rose after krill oil and fish oil consumption compared 
with olive oil consumption and reached steady state by 2 
h as shown in Figure 2. There was a significant difference 
in EPA concentrations between krill oil and fish oil con-
sumption at 4 h. As expected, no significant changes in 
the proportion of EPA were observed following olive oil 
consumption. 
There were no consistent increases in DHA following 
krill oil and fish oil consumption (Figure 2). There was a 
significant difference between krill oil and olive oil at 5 h 
(p=0.010), and between fish oil and olive at 1 h (p<0.01) 
and 5 h (p=0.027). There was a significant difference in 
DHA between krill oil and fish oil at 2 h (p=0.040). The 
proportions of DPA after krill oil and fish oil consump-
tion were not significantly different from each other or 
from olive oil, apart from at 5 h of krill oil consumption 
which was significantly greater in comparison with olive 
oil (p=0.026). 
There were no significant effects of diet intervention on 
the concentration of plasma AA between three test meals. 
The concentrations of plasma AA showed significant dif-
ferences between krill oil and fish oil consumption at 3 h 
(p=0.043). The concentrations of linoleic acid (LA) and 
oleic acid (OA) after krill oil and fish oil consumption 
were not significantly different from each other or from 
olive oil. There was one exception at 2 h with fish oil 
consumption resulting in significantly greater concentra-
tions in comparison with olive oil (p=0.039). 
The postprandial net iAUC values of EPA in both krill 
oil and fish oil groups were significantly different from 
the olive oil group (p=0.010 and p=0.017, respectively), 
however, there was no significant difference between krill 
oil and fish oil groups (p=0.850) (Figure 2). While the net 
iAUC for the fish oil group was not significantly different 
from the krill oil, the fish oil group had a 12% higher val-
ue than the krill oil group (p>0.05). The net iAUC values 
for the total n-3 PUFA (EPA, DPA, and DHA) were sig-
nificantly greater after krill oil and fish oil consumption 
compared with olive oil consumption (p<0.001), however 
there was no significant difference between krill oil and 
fish oil groups (p=0.980) (Figure 2). 
 
Plasma fatty acid composition in TAG and PL 
The plasma LC PUFA in TAG and PL fractions from four 
 
 
 
Figure 2. Postprandial changes in plasma oleic acid and polyunsaturated fatty acid concentrations after consuming test meals containing 
krill oil, fish oil or olive oil (control). (A) plasma EPA; (B) plasma DPA; (C) plasma DHA; (D) plasma AA; (E) plasma OA; (F) plasma 
LA; (G) net incremental area under the curve (net iAUC) of plasma EPA; (H) net iAUC of plasma DHA; (I) net iAUC of total LC n-3 
PUFA including EPA, DHA, and DPA. Values are expressed as mean ± SEM for 10 participants. # and * in graphs (A) and (C), indicate 
significant differences between fish oil (#) or krill oil (*) and olive oil (p<0.05) consumptions. Different superscripts in graphs G-I 
represent significant difference among the test meal consumptions. AA, arachidonic acid; EPA, eicosapentaenoic acid; DPA, 
docosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; OA, oleic acid.  
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randomly selected participants, were analysed and the 
data are shown in Figure 3. In the fish oil group for plas-
ma TAG, there was a trend (non-significant) for the EPA 
and DHA to increase with time (data not shown). This 
was reflected in the net iAUC (panels A and B Figure 3). 
In the krill oil group for plasma PL fraction, there was a 
trend for both EPA and DHA to increase with time (data 
not shown). This was reflected in the net iAUC (panels C 
and D Figure 3).  
 
Postprandial plasma and chylomicron lipids 
The baseline total cholesterol, TAG, HDL, LDL, and glu-
cose in plasma and chylomicron were not significantly 
different between test meals (Tables 2 and 3). There were 
no significant effects of the test meals on plasma lipids 
and glucose, although there were significant time effects 
on all parameters (cholesterol, TAG, LDL, HDL, and 
glucose) in plasma, and cholesterol and TAG in chylomi-
cron (Table 2 and Table 3). Plasma TAG increased after 1 
to 3 h consumption for all three test meals, however these 
changes were not statistically significant (Table 2). There 
were also no significant effects of the test meals on chy-
lomicron lipids and glucose (only cholesterol and TAG 
presented in Table 3) except for fish oil consumption, 
which resulted in significantly higher TAG at 1 and 2 h 
(p<0.05). By 4 h, the TAG in chylomicron had returned to 
the baseline. The net iAUC values of changes in lipids 
and glucose in plasma and chylomicron were also not 
significantly different between the test meals (data not 
shown). 
DISCUSSION 
This crossover study investigated the postprandial LC n-3 
PUFA responses to krill oil and fish oil consumption in 
healthy women, in a randomised crossover design. In 
order to maintain the participants being blinded to which 
treatment they were taking, the study design provided 
either 5 capsules (5 g) of krill oil or 5 capsules (5 g) of 
fish oil to participants. This design resulted in a 31% low-
er dose of EPA and 37% lower dose of total LC n-3 
PUFA dose from krill oil than fish oil in the breakfast 
meal (542 mg EPA and 907 mg LC n-3 PUFA from krill 
oil versus 786 mg EPA and 1441 mg LC n-3 PUFA from 
fish oil). 
The main finding from this study was that the plasma 
EPA rose to the similar extent after krill oil and fish oil 
consumption (Figure 2). Neither DHA nor DPA showed 
significant elevations over the course of the study. Other 
postprandial studies comparing the effects of krill oil and 
fish oil have shown that in the first 72 hours, the EPA 
incorporation into plasma lipids occurred more efficiently 
compared with DHA.24 While there is no clear explana-
tion for this result, apart from differences in the turnover 
rates of EPA and DHA in plasma lipid fractions, the in-
crease in EPA over the 5-hour postprandial period at the 
present study is consistent with those studies. It is unlike-
ly that the EPA arose from endogenous ALA metabolism. 
Firstly, the EPA content of the capsules was 15 to 21 
times greater than the ALA content. Secondly, the ratio of 
LA to ALA in the breakfast meal was greater than 16:1, 
making it unlikely that ALA was significantly metabo-
 
 
 
Figure 3. Postprandial changes in EPA and DHA composition in plasma TAG and PL after consuming test meals containing krill oil, fish 
oil or olive oil (control) (pilot data). (A) Net incremental area under the curve (Net iAUC) of EPA in TAG; (B) Net iAUC of DHA in 
TAG; (C) Net iAUC of EPA in PL; (D) Net iAUC of DHA in PL. Values of net iAUC from baseline are expressed as % of TAG or PL 
fatty acids * hour (mean ± SEM) for 4 participants. There were no significant differences observed between krill oil and fish oil 
consumption over the 5-hour postprandial period. TAG, triglyceride; PL, phospholipids 
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lised to EPA in this study. 
There are a number of possible explanations why a 
31% lower dose of EPA from krill oil compared with fish 
oil could result in a similar concentration of plasma EPA. 
Firstly, while there was a 12% higher net iAUC for EPA 
in the fish oil group, this was not significantly different to 
the krill oil group. It is possible that with a higher number 
of participants a significant difference might have been 
found in the study. Secondly, in krill oil, it has been re-
ported that EPA is mainly found in the free fatty acids 
and phospholipids (phosphatidycholine and phosphatidyl-
ethanolamine) compared with fish oils where the EPA is 
in the TAG.22 The digestion and absorption of fatty acids 
from PL and TAG do not follow identical pathways, as 
reported in previous studies.37-39 These authors proposed 
that dietary phospholipids might be transported into the 
bloodstream, following digestion and absorption, in chy-
lomicrons, HDL or as lyso-phospholipids bound to albu-
min. In contrast, dietary TAG fatty acids are mostly 
transported via chylomicrons, followed by uptake in the 
liver and redistribution of the TAG fatty acids into differ-
ent lipids of exported lipoproteins (very low-density lipo-
proteins, etc.).37-39 There have been no available studies 
looking at these different digestion and absorption possi-
bilities for LC n-3 PUFA from krill oil, however we sug-
gest that over the time of 5 h postprandial period, the 
EPA from the krill oil lipids may be more efficiently di-
gested and absorbed than EPA from fish oil TAG, result-
ing in a similar short-term EPA concentration (bioavaila-
bility) in plasma lipids. 
Krill oil also contains a higher level of free fatty acids 
(FFA) compared with fish oil.22 FFA have been shown to 
result in an increased apparent bioavailability compared 
with esterified forms of LC n-3 PUFA.28 While no mech-
anisms have been established, it has been suggested the 
reason is that pancreatic lipase has a significantly reduced 
efficiency towards hydrolysis of EPA and DHA from fish 
oils.40 Thus, both the free fatty acids and phospholipids 
from krill oil might contribute to the increased short-term 
uptake of EPA into plasma lipids compared with fish oil, 
which might help to explain the present results. 
In the current study, we examined EPA, DPA, and 
DHA levels in plasma TAG and PL in four of the partici-
pants and these preliminary data revealed that EPA from 
krill oil was mainly taken up in the PL fraction while 
EPA from fish oil was found mainly in the TAG fraction, 
highlighting that in the postprandial period EPA from oils 
rich in TAG (fish oil) or rich in PL and FFA (krill oil) are 
not incorporated into plasma lipids in the same manner. It 
is possible that such differences might contribute to an 
explanation of why a 31% lower EPA dose from krill oil 
might lead to the similar total plasma concentration of 
EPA over the 5 h postprandial period in this study. Fur-
ther studies are required to understand the fate and rate 
Table 2. Postprandial changes in plasma lipids and glucose 
 
mmol/L Test meal Time 0 Time 1 Time 2 Time 3 Time 4 Time 5  p value 
Cholesterol Olive oil 5.1 (0.2) 4.9 (0.2) 4.8 (0.2)* 4.8 (0.2)* 4.8 (0.2)* 4.8 (0.2) Time 0.042 
 
Fish oil 4.8 (0.2) 4.7 (0.2) 4.7 (0.2) 4.7 (0.2) 4.8 (0.2) 4.8 (0.2) Meal 0.428 
  Krill oil 4.9 (0.2) 4.9 (0.2) 4.7 (0.2) 4.9 (0.2) 4.9 (0.2) 4.9 (0.2) Interaction 0.213 
          
TAG Olive oil 0.9 (0.1) 1.0 (0.2) 1.0 (0.2) 1.0 (0.2) 1.0 (0.2) 0.9 (0.2) Time 0.005 
 Fish oil 1.0 (0.1) 1.2 (0.2) 1.2 (0.2) 1.1 (0.2) 1.0 (0.1) 0.9 (0.1) Meal 0.477 
 Krill oil 1.0 (0.1) 1.2 (0.2) 1.1 (0.2) 1.1 (0.2) 1.0 (0.1) 0.9 (0.1) Interaction 0.628           
LDL Olive oil 3.3 (0.2) 3.1 (0.1)* 3.0 (0.1)* 3.1 (0.1)* 3.1 (0.1)* 3.1 (0.2) Time 0.000 
 
Fish oil 3.0 (0.1) 2.8 (0.1) 2.8 (0.1) 2.9 (0.1) 3.0 (0.2) 3.0 (0.2) Meal 0.096 
  Krill oil 3.0 (0.1) 3.0 (0.1) 2.9 (0.1) 3.0 (0.2) 3.1 (0.1) 3.1 (0.1) Interaction 0.069 
          
HDL Olive oil 1.4 (0.1) 1.3 (0.1) 1.3 (0.1)* 1.3 (0.1)* 1.3 (0.1)* 1.3 (0.1)* Time 0.000 
 Fish oil 1.4 (0.1) 1.4 (0.1)
* 1.3 (0.1)* 1.3 (0.1)* 1.4 (0.1)* 1.4 (0.1) Meal 0.227 
 
Krill oil 1.4 (0.1) 1.4 (0.1) 1.3 (0.1) 1.4 (0.1) 1.3 (0.1) 1.4 (0.1) Interaction 0.801 
          
Glucose Olive oil 5.4 (0.1) 6.0 (0.4) 5.2 (0.2) 4.9 (0.1) 5.0 (0.1) 5.0 (0.1) Time 0.000 
 Fish oil 5.4 (0.2) 5.8 (0.2) 5.2 (0.2) 5.2 (0.2) 5.2 (0.1) 5.1 (0.1) Meal 0.674 
  Krill oil 5.4 (0.1) 6.1 (0.4)* 5.4 (0.1) 5.1 (0.1) 5.1 (0.1) 5.0 (0.1) Interaction 0.540 
 
TAG: triglycerides; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol. 
Values are expressed as mean (±SE) for 10 women.  
*Significant difference (p<0.05) compared with the baseline for each test meal.  
 
 
Table 3. Postprandial changes in chylomicron lipids 
 
mmol/L Test meal Time 0 Time 1 Time 2 Time 3 Time 4 Time 5 p value 
Cholesterol Olive oil 2.2 (0.2) 2.1 (0.2) 2.2 (0.1) 2.3 (0.2) 2.1 (0.2) 2.4 (0.1) Time 0.555 
Fish oil 2.1 (0.2) 2.3 (0.1) 2.3 (0.2) 2.1 (0.1) 2.0 )0.5) 2.2 (0.1) Meal 0.107 
  Krill oil 2.4 (0.1) 2.4 (0.1) 2.4 (0.2) 2.3 (0.2) 2.3 (0.2) 2.4 (0.1) Interaction 0.870 
          
TAG Olive oil 0.4 (0.1) 0.7 (0.1) 0.6 (0.1) 0.7 (0.1) 0.5 (0.1) 0.6 (0.1) Time 0.001 
Fish oil 0.6 (0.2) 0.9 (0.2)* 0.8 (0.2)* 0.7 (0.1) 0.6 (0.1) 0.5 (0.1) Meal 0.541 
Krill oil 0.6 (0.1) 0.8 (0.1) 0.7 (0.1) 0.7 (0.1) 0.6 (0.1) 0.5 (0.1) Interaction 0.254 
 
TAG: triglycerides. 
Values are expressed as mean (±SE) for 10 women.  
*Significant difference (p<0.05) compared with the baseline for each test meal.  
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of incorporation of LC n-3 PUFA from dietary PL. 
These data over the 5-hour postprandial period do not 
mean that studies conducted over longer periods such as 
4+ weeks would yield the same results. For example, it 
has been reported that short-term (postprandial studies) 
may reveal different effects compared with longer-term 
studies (weeks), in terms of incorporation of LC n-3 
PUFA into plasma lipid fractions. Studies by Sadou et 
al42 and Cook et al43 reported that uptake of LC n-3 
PUFA into plasma lipids in the postprandial period (<12 h) 
did not mirror the data after more than four weeks of 
PUFA ingestion. Sadou et al41 found that at 8 h, the EPA 
level in plasma PL was only 67% of the plasma TAG 
EPA levels, while at 30 days the plasma PL EPA levels 
were 329% of the TAG EPA value. Cook et al42 showed 
that significant differences in uptake of LC n-3 PUFA 
between plasma PL and TAG fractions observed at 12 h 
postprandially were not evident after two weeks, at which 
time incorporation of LC n-3 PUFA into plasma phospha-
tidylcholine was not significantly different between plas-
ma TAG and PL fractions. A possible explanation is that 
the plasma levels of a fatty acid in short-term (postpran-
dial state) are a function of absorption efficiency and tis-
sue uptake or metabolism. In longer-term, the plasma 
level of fatty acids is governed by these factors as well as 
by the incorporation into tissues and turnover of the LC 
n-3 PUFA. The n-3 index is regarded as the most reliable 
marker of LC n-3 PUFA in tissue stores, and it has been 
reported to be inversely associated with the cardio-
metabolic risks.43 Further long term studies measuring the 
n-3 index are highly recommended in order to better un-
derstand the potential health benefits of krill oil consump-
tion. 
In the present study, the plasma EPA reached a plateau 
(steady state) at 3 h, however Schuchardt et al17 showed 
that EPA concentrations in plasma PL increased steadily 
from the baseline up to 8 h postprandially for both krill 
oil and fish oil groups. Kohler et al25 reported similar 
findings, in that EPA levels rose after krill oil or fish oil 
consumption, and that the Tmax for plasma TAG EPA 
was approximately 10 h and for plasma TAG DHA was 
approximately 20 h. In contrast, in their study, the Tmax 
for plasma PL EPA was between 16 h and 25 h, while 
that for plasma PL DHA was between 48 h and 55 h. This 
indicates that studies of short duration, such as the present 
study, do not necessarily give sufficient information to 
make adequate comparisons between krill oil and fish oil, 
since the Tmax values for EPA were reported to be be-
tween 10 h and 20 h in plasma lipid fractions.26 In the 
future, studies of a longer duration should be considered. 
However, such studies are likely to be less controlled and 
have significant practical issues such as what foods 
should be allowed to consume for subsequent meals after 
the test breakfast (lunch, dinner, etc.).  
The data from Kohler et al25 also indicated differences 
in the incorporation of LC n-3 PUFA between krill oil 
and fish oil in the plasma PL and TAG fractions. They 
found that over the 72 h of the study, there was a signifi-
cantly greater (1.5 times, p<0.003) incremental area under 
the curve (iAUC) for EPA plus DHA in plasma PL after 
krill oil consumption compared with fish oil consumption, 
whereas the iAUC for EPA plus DHA was not different 
between the two oils in plasma TAG. The present study 
also showed a trend for increased net iAUC for LC n-3 
PUFA in plasma PL for krill oil compared with fish oil, 
although the results are limited by the small number of 
participants. A higher incorporation of EPA into plasma 
PL from krill oil consumption compared with fish oil 
consumption has been reported by Kohler et al.17, 25 Con-
sistently, Lemaitre-Delaunay et al44 have reported differ-
ential labelling of plasma lipid fractions over a 6 h period 
for 13C-DHA administered in phosphatidylcholine form 
or TAG form. Those data support the idea that PUFA 
bound to PL or TAG are not digested, absorbed, and sub-
sequently metabolised via identical pathways. 
In the present study and those by Kohler et al25 and 
Schuchardt et al,17 it was clear that there was considerable 
variability between the individual responses of partici-
pants to the treatments. It appears from the literature that 
the inter-participant variability in response to the treat-
ments occurs in both genders and different age groups. 
The present study included young women, while the 
study of Schuchardt et al17 focused on young male partic-
ipants, and that of Kohler et al25 looked at the older male 
and female participants. Ghasemifard et al28 reviewed in 
detail the factors which could influence the apparent bio-
availability of LC n-3 PUFA. These included matrix of 
the food, fat content of the test meal, age, gender, dose 
rate, absorption efficiency (faecal loss), and body weight 
of the participants. Typically, in studies comparing krill 
oil and fish oil, these factors are not controlled for and 
presumably contribute to the inter-participant variability.  
The present study has strengths in that it was a random-
ised crossover postprandial study conducted in a con-
trolled location, which included a control group (olive oil) 
and was conducted with women participants who were all 
of a similar age. Nonetheless, that we have not studied 
men is a limitation. The single gender design was intend-
ed to minimise variations between participants. Available 
studies have either not been gender-specific or of men 
with large inter-participant variations. The present study, 
with its focus on young women, was more likely to pro-
vide useful information on fatty acid bioavailability from 
krill compared with fish oil. However, it is acknowledged 
that the study had several limitations which included be-
ing a short time frame (5 h), having a small number of 
participants (n=10), with participants not totally blinded 
to test meals (capsule contents have a different colour), 
and the dose of total LC n-3 PUFA for krill oil being 37% 
lower than for fish oil. It is possible that the small partici-
pant number has obscured the differences between krill 
oil and fish oil supplementations. Further studies with a 
larger number of participants are required to determine 
whether there is a significant difference in the postprandi-
al plasma EPA concentrations between the consumption 
of two marine oils. It is also important to analyse the lipid 
fractions in plasma using novel approaches, such as lip-
idomics, in order to assess the incorporation of the LC n-3 
fatty acids into the very large number of molecular spe-
cies of different lipids which exist in plasma.45 It is worth 
noting that, as discussed by Ghasemifard et al,28 a higher 
plasma concentration does not necessarily equate to a 
higher ‘bioavailability’, since for true bioavailability the 
faecal losses must be determined. Despite this, most stud-
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ies comparing krill oil and fish oil use the term bioavaila-
bility. 
 
Conclusions 
In this study, we have found that, in young women, 5 g of 
krill oil supplementation resulted in similarly high plasma 
EPA concentrations to the same amount of fish oil over a 
5-hour postprandial period, despite krill oil containing 
31% lower EPA than the fish oil. This is relevant to con-
sumers who are likely choose to consume an equal num-
ber of capsules of krill oil or fish oil rather than choose 
the dose of LC n-3 PUFA. These results suggest that EPA 
from krill oil may be more efficiently incorporated into 
plasma due to the high content of phospholipids and free 
fatty acids in this oil. Further large long-term studies are 
warranted to determine the impact of krill oil supplemen-
tation on long-term tissue stores and the consequential 
clinical benefits in comparison with fish oil. 
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